Abacioglu U, Caglar H, Atasoy B M, Abdulloev T, Akgun Z, Kilic T
Marmara University Hospital, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey.
J BUON. 2010 Apr-Jun;15(2):274-80.
To evaluate the efficacy of gamma knife radiosurgery (GKRS) for the treatment of brain metastases from non small cell lung cancer (NSCLC) and find out the prognostic factors for overall survival.
Between February 1997 and August 2003 100 patients underwent treatment for 184 brain metastases from NSCLC, either for recurrence (n=49) or with a new diagnosis (n=51). Median age was 55 years and 77 patients were male. Seventy-eight of the patients received whole brain radiotherapy (WBRT) prior to or after GKRS and 26 patients had surgical removal of the metastasis. Imaging and clinical status were monitored every 3 months following treatment. Kaplan-Meier survival curves, Cox proportional hazards regression for risk factor analysis were used.
The median follow up after the procedure was 8 months and after the diagnosis 11 months. The median overall survival for all patients was 9 months from the date of GKRS and 14 months from the diagnosis of brain metastasis. Local tumor control was achieved in 95% of the lesions. In multivariate analysis, adenocarcinoma histology, Karnofsky performance status (KPS) score > 80, 1-3 metastases and tumor diameter <2 cm were related to longer survival. Addition of WBRT did not have any effect on overall survival.
Gamma knife surgery appears to be effective in treating patients with brain metastases from NSCLC, either alone or with WBRT in selected groups of patients.
评估伽玛刀放射外科手术(GKRS)治疗非小细胞肺癌(NSCLC)脑转移瘤的疗效,并找出总生存的预后因素。
1997年2月至2003年8月期间,100例患者接受了针对184个NSCLC脑转移瘤的治疗,其中49例为复发病例,51例为新诊断病例。中位年龄为55岁,男性77例。78例患者在GKRS之前或之后接受了全脑放疗(WBRT),26例患者进行了转移瘤手术切除。治疗后每3个月监测一次影像学和临床状态。采用Kaplan-Meier生存曲线、Cox比例风险回归进行危险因素分析。
手术后中位随访时间为8个月,诊断后为11个月。所有患者从GKRS日期起的中位总生存时间为9个月,从脑转移瘤诊断起为14个月。95%的病灶实现了局部肿瘤控制。多因素分析显示,腺癌组织学类型、卡诺夫斯基功能状态(KPS)评分>80、1-3个转移灶以及肿瘤直径<2 cm与较长生存期相关。添加WBRT对总生存无任何影响。
伽玛刀手术似乎对治疗NSCLC脑转移瘤患者有效,无论是单独使用还是在特定患者组中与WBRT联合使用。